



Office of Commissioner
Mark R. Meador

UNITED STATES OF AMERICA
Federal Trade Commission
WASHINGTON, D.C. 20580

Statement of Commissioner Mark R. Meador
Regarding *Federal Trade Commission et al. v. Martin Shkreli*, 1:20-cv-00706 (S.D.N.Y)
FTC Matter No. 2610130

October 13, 2026

The Commission authorized agency staff to file a contempt action today against Martin Shkreli for flagrantly violating the 2022 permanent injunction prohibiting him from participating, directly or indirectly, in any part of the pharmaceutical industry. Mr. Shkreli has repeatedly ignored the injunction's clear and unambiguous prohibitions and has shown little regard for the obligations imposed on him as a result of his prior illegal conduct. His ongoing efforts to participate in the pharmaceutical industry, despite the court-ordered ban, reflect a deliberate pattern of defiance that undermines the purpose and efficacy of the court's remedy and the law.

The extensive record compiled by FTC staff shows that Mr. Shkreli chose to blatantly disregard the order after leaving prison. Among other actions, he has traded pharmaceutical stocks and actively sought to influence the business and management of multiple pharmaceutical companies through public commentary, in violation of the terms of the injunction. Because the injunction is permanent, any violations require strong and meaningful enforcement. A lifetime industry ban is only effective if breaches are met with consequences commensurate with the seriousness of the order.

On this basis, I strongly support asking the court to hold Mr. Shkreli in civil contempt and to impose appropriate sanctions. Given his repeated violations, escalating consequences for future misconduct—including financial penalties and, if necessary, incarceration—are warranted. These measures are essential to uphold the court's order and convey to all industry participants that the Commission will vigilantly monitor and fully enforce its remedies.